e-learning
resources
Stockholm 2002
Tuesday 17.09.2002
Sarcoidosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis
O. Baranova, V. Amosov, M. Kameneva, T. Ses, V. Voinov (Saint-Petersburg, Russia)
Source:
Annual Congress 2002 - Sarcoidosis
Session:
Sarcoidosis
Session type:
Poster Discussion
Number:
2750
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Baranova, V. Amosov, M. Kameneva, T. Ses, V. Voinov (Saint-Petersburg, Russia). The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis. Eur Respir J 2002; 20: Suppl. 38, 2750
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 85s
Year: 2007
The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 713s
Year: 2004
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy
Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases
Year: 2007
The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
Efficacy of different preoperational treatment in patients with destructive pulmonary TB
Source: Eur Respir J 2005; 26: Suppl. 49, 688s
Year: 2005
The pharmacotherapy options for the intensive treatment phase in patients with primarily diagnosed pulmonary tuberculosis
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
Safety of corticosteroid therapy in patients with pulmonary sarcoidosis
Source: International Congress 2017 – The many faces of sarcoidosis
Year: 2017
Our clinical experience in surgical therapy of patients with bronchiectasis
Source: Eur Respir J 2002; 20: Suppl. 38, 344s
Year: 2002
Rituximab in the treatment of refractory pulmonary sarcoidosis
Source: Eur Respir J 2014; 43: 1525-1528
Year: 2014
The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up)
Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Year: 2010
The effect of pulmonary rehabilitation programme in patients with pulmonary sarcoidosis
Source: Annual Congress 2011 - Rehabilitation, outcome measures and effects
Year: 2011
The clinico-immunological evaluation of the ribomunyl therapy in complex treatment of COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 674s
Year: 2006
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007
Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis
Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Year: 2020
Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017
The clinical value of intravenous pulse therapy in first retreatment pulmonary tuberculosis patients
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Methotrexate in the treatment of the chronic form of pulmonary and extra - pulmonary sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004
Standard therapy for sarcoidosis
Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept